Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: A nested case-control study

British Journal of Cancer

Volumn 102, Issue 9, 2010, Pages 1415-1421

  Bradley, M C ^a   Hughes, C M ^a   Cantwell, M M ^a   Napolitano, G ^b   Murray, L J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Aspirin; GPRD; NSAIDs; Pancreatic cancer

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FENAMIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PROPIONIC ACID DERIVATIVE; PROTON PUMP INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRINKING BEHAVIOR; DRUG MEGADOSE; DRUG USE; FEMALE; GENERAL PRACTICE; HORMONE SUBSTITUTION; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK REDUCTION; SEX RATIO; SMOKING; STATISTICAL ANALYSIS; STEROID THERAPY; UNITED KINGDOM;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY MASS INDEX; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DATABASES AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; ODDS RATIO; PANCREATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; SMOKING;

EID: 77951666450     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605636     Document Type: Article

References (37)

1. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A (2009) Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 100: 551-557
2. Anderson KE, Johnson TW, Lazovich D, Folsom AR (2002a) Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94: 1168-1171 (Pubitemid 34919054)
3. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885-895 (Pubitemid 44315981)
4. Arellano F, Yood M, Wentworth C, Oliveria S, Rivero E, Verma A, Rothman K (2006) Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription nonsteroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmaco-epidemiol Drug Saf 15: 861-872
5. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG, APPROVe Trial Investigators (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131: 1674-1682
6. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET, APC Study Investigators (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873-884 (Pubitemid 44315980)
7. Capurso G, Schunemann HJ, Terrenato I, Moretti A, Koch M, Muti P, Capurso L, Delle Fave G (2007) Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Aliment Pharmacol Ther 26: 1089-1099
8. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials'. J Natl Cancer Inst 101: 256-266
9. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S (2000) Non steroidal Anti-inflammatory Drugs and Risk of digestive cancers at sites other than the Large Bowel. Cancer Epidemiol Biomarkers Prev 9: 119-123
10. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294: 47-55 (Pubitemid 41002838)
11. Ding H, Han C, Gibson-D'Ambrosio R, Steele VE, D'Ambrosio SM (2003) Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1. Int J Cancer 107: 830-836
12. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613
13. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Abbate R, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low dose aspirin. Br J Cancer 88: 684-688
14. Garcia Rodriguez LA, Perez Gutthann S (1998) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45: 419-425
15. Garcia-Rodriguez LA, Huerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Epidemiology 12: 88-93
16. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003) Effects of nonsteroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC cancer 3: 28-40
17. GPRD 2009). 07/2009-last update, GPRD Bibliography [homepage of GPRD], [online]. Available: http://www.gprd.com/bibliography/[15/12/2009]
18. Hollowell J (1997) The General Practice Research Database: quality of morbidity data. Popul Trends 87: 36-40
19. Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, Thun MJ (2004) Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96: 524-528
20. Jemal A, Siegel R, Ward E, Murray T, XU J, Thun M (2007) Cancer statistics 2007. CA Cancer J Clin 57: 43-66
21. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J (Clin Res Ed) 302: 766-768
22. Jick H, Jick SS, Derby LE, Vasilakis C, Myers M, Meier C (1997) Calcium channel blockers and risk of cancer. Lancet 349: 525-528 (Pubitemid 27092790)
23. Jick H, Terris BZ, Derby LE, Jick SS (1992) Further validation of information recorded on a general practicioner based computerised data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1: 347-349
24. Khuder S, Mutgi A (2001) Breast Cancer and NSAID use a meta-analysis. Br J Cancer 84: 1118-1192
25. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Br Med J (Clin Res Ed) 320: 1642-1646
26. Larsson SC, Giovannucci E, Bergkvist L, Wolk A (2006) Aspirin and Non steroidal anti-inflammatory drug use and the risk of pancreatic cancer: a meta analysis. Cancer Epidemiol Biomarkers Prev 15: 2561-2564
27. Lynch P (2006) Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory? Gastroenterology 131: 2003-2005
28. Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22: 303-309
29. Menezes RJ, Huber KR, Mahoney MC, Moysich KB (2002) Regular use of aspirin and pancreatic cancer risk. BMC Public Health 2: 18-24
30. Naruse T, Nishida Y, Hosono K, Ishiguro N (2006) Meloxicam inhibits osteocarcoma growth, invasiveness and metastasis by cox-2 dependent and independent routes. Carcinogenesis 27: 584-592
31. Ratnasinghe L, Graubard B, Kahle L, Tangrea J, Taylor P, Hawk E (2004) Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24: 3177-3184
32. Schernhammer ES, Kang J, Chan AT, Michaud DS, Skinner HG, Giovannucci E, Colditz GA, Fuchs CS (2004) A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96: 22-28 (Pubitemid 38180956)
33. Schreinmachers D, Everson R (1994) Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5: 138-146
34. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88: 1687-1692
35. Van Staa T, Abenhaim L (1994) The quality of information recorded on a UK Database of Primary Care Records: a study of hospitalizations due to hypoglycaemia and other conditions. Pharmacoepidemiol Drug Saf 3: 15-21
36. World Health Organisation Working Group 2008). 14/08/2008-last update, About the ATC/DDD system. Available: http://www.whocc.no/atcddd/atcsystem.html [25/01/2009]
37. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD (2007) Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133: 748-754